Hiroyuki Seimiya Selected Research

Tankyrases

1/2021	Novel tankyrase inhibitors suppress TDP-43 aggregate formation.
9/2020	Crossroads of telomere biology and anticancer drug discovery.
1/2020	Tankyrase promotes primary precursor miRNA processing to precursor miRNA.
1/2020	Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
1/2020	Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
11/2019	Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
5/2019	Meeting report of the 14th Japan-Korea joint symposium on cancer and aging research: current status of translational research and approaches to precision medicine.
12/2018	RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
11/2018	MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs.
7/2017	mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroyuki Seimiya Research Topics

Disease

41	Neoplasms (Cancer) 07/2022 - 04/2002
10	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 06/2016
6	Carcinogenesis 12/2018 - 07/2002
5	Glioma (Gliomas) 05/2019 - 08/2009
4	Arthrogryposis renal dysfunction cholestasis syndrome 01/2020 - 03/2004
4	AIDS-Related Complex (ARC) 01/2020 - 03/2004
4	Prostatic Neoplasms (Prostate Cancer) 09/2014 - 11/2010
3	Stomach Neoplasms (Stomach Cancer) 01/2021 - 11/2019
2	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2020
2	Residual Neoplasm 03/2020 - 11/2019
2	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 12/2018 - 01/2017
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2018 - 10/2008
2	Adenocarcinoma of Lung 04/2010 - 10/2008
2	Lung Neoplasms (Lung Cancer) 10/2008 - 09/2004
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2021
1	TDP-43 Proteinopathies 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 09/2020
1	Circulating Neoplastic Cells 02/2020
1	Hypersensitivity (Allergy) 01/2020
1	Neutropenia 01/2020
1	Disease Progression 01/2020
1	Type 2 Diabetes Mellitus (MODY) 11/2018
1	Urinary Bladder Neoplasms (Bladder Cancer) 02/2017
1	Non-Muscle Invasive Bladder Neoplasms 02/2017
1	Glioblastoma (Glioblastoma Multiforme) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 08/2015
1	Adenocarcinoma 08/2013
1	De Lange Syndrome (Cornelia De Lange Syndrome) 09/2012

Drug/Important Bio-Agent (IBA)

18	TankyrasesIBA 01/2021 - 04/2002
9	LigandsIBA 11/2020 - 03/2012
9	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2020 - 07/2002
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2007
6	Pharmaceutical PreparationsIBA 10/2020 - 07/2002
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 06/2007
5	EnzymesIBA 11/2019 - 08/2009
4	telomestatinIBA 10/2021 - 03/2012
4	CateninsIBA 01/2020 - 01/2017
4	Biomarkers (Surrogate Marker)IBA 12/2018 - 04/2010
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 09/2020 - 01/2007
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 11/2019
3	MST 312IBA 10/2018 - 07/2002
3	ATP Citrate (pro-S)-Lyase (Citrate Synthase, ATP)IBA 07/2014 - 10/2008
2	RNA (Ribonucleic Acid)IBA 02/2021 - 02/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2016
2	Biological ProductsIBA 11/2020 - 03/2004
2	regorafenibIBA 02/2020 - 06/2016
2	Cadherins (E-Cadherin)IBA 02/2017 - 08/2013
2	Phosphotransferases (Kinase)IBA 06/2016 - 10/2008
2	Fatty Acids (Saturated Fatty Acids)IBA 07/2014 - 08/2009
2	Hormones (Hormone)IBA 07/2012 - 11/2010
2	Adenosine Diphosphate (ADP)IBA 03/2004 - 04/2002
1	OxazolesIBA 10/2021
1	lamellarin 14IBA 05/2021
1	Interferon-gamma (Interferon, gamma)IBA 02/2021
1	OligonucleotidesIBA 02/2021
1	RNA Splicing FactorsIBA 02/2021
1	RamucirumabIBA 01/2021
1	Alkenes (Olefins)IBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2021
1	Interleukin-8 (Interleukin 8)IBA 01/2021
1	Untranslated RNA (Noncoding RNA)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	AzidesIBA 11/2020
1	Fluorouracil (Carac)FDA LinkGeneric 03/2020
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	artemisinin (artemisinine)IBA 01/2020
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020
1	trifluridine tipiracil drug combinationIBA 01/2020
1	ErbB Receptors (EGF Receptor)IBA 11/2019
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2019
1	TCF Transcription FactorsIBA 12/2018
1	CalpainIBA 11/2018
1	Peptide Hydrolases (Proteases)FDA Link 11/2018
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 10/2018
1	Lamin Type A (Lamin A)IBA 10/2018
1	Transforming Growth Factors (Transforming Growth Factor)IBA 02/2017
1	Alkylating AgentsIBA 01/2017
1	Carrier Proteins (Binding Protein)IBA 01/2017
1	Temozolomide (Temodar)FDA LinkGeneric 01/2017
1	ChemokinesIBA 06/2016
1	Angiogenic ProteinsIBA 02/2016
1	olaparibIBA 08/2015
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2015
1	Endoplasmic Reticulum Chaperone BiPIBA 09/2014
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 09/2014
1	Triglycerides (Triacylglycerol)IBA 07/2014
1	Antineoplastic Agents (Antineoplastics)IBA 03/2013
1	CohesinsIBA 09/2012
1	Growth InhibitorsIBA 07/2012

Therapy/Procedure

16	Therapeutics 07/2022 - 01/2005
1	Treatment Delay 01/2020
1	Aftercare (After-Treatment) 11/2019
1	Precision Medicine 05/2019
1	Oral Administration 12/2018
1	Salvage Therapy 06/2016